[Corrections] Corrections
Weston P S J, Nicholas J M, Henley S M D, et al. Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol 2018; 17: 123 –32—In table 3 of this Article, data for figure 30-min recall were incorrectly recorded. Data in this row have been corrected in the online version as of March 13, 2018. (Source: Lancet Neurology)
Source: Lancet Neurology - March 14, 2018 Category: Neurology Tags: Corrections Source Type: research
[Comment] Mapping brain networks in patients with focal epilepsy
Epilepsy is one of the most common neurological disorders, affecting more than 50 million people worldwide. Around 70% of patients with epilepsy respond to antiepileptic drugs.1 For patients who do not respond, surgery is an accepted treatment option.2 Seizure recurrence after resection is seen in 30 –70% of patients and follows predictable slopes based on multiple factors, including the duration of epilepsy, history of generalised tonic seizures, frequency of preoperative seizures, and the presumptive pathological cause of epilepsy on MRI. (Source: Lancet Neurology)
Source: Lancet Neurology - March 14, 2018 Category: Neurology Authors: Imad M Najm Tags: Comment Source Type: research
[Comment] A crystal ball for survival for spinocerebellar ataxias?
Death is an unequivocal clinical endpoint. Although each of us must accept the harsh reality of 100% mortality, prolonging survival has been, and will be, one of the major goals of medicine. Spinocerebellar ataxias are a group of autosomal dominant neurodegenerative disorders, most of which show relentless progression, often resulting in total disability and premature death.1 SCA1, SCA2, SCA3, and SCA6 are among the most common spinocerebellar ataxias and caused by expanded CAG trinucleotide repeats encoding polyglutamine (polyQ), which belong to the same class of mutations as those of Huntington's disease, spinal and bulb...
Source: Lancet Neurology - March 14, 2018 Category: Neurology Authors: Tetsuo Ashizawa Tags: Comment Source Type: research
[Editorial] Accelerating research for Parkinson's disease
Despite considerable ongoing translational and clinical research efforts, no disease-modifying drugs have been approved for Parkinson's disease. The Accelerating Medicines Partnership Parkinson's disease (AMP PD) programme, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and one non-profit organisation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate exis...
Source: Lancet Neurology - March 14, 2018 Category: Neurology Authors: The Lancet Neurology Tags: Editorial Source Type: research
[Correspondence] International Classification of Headache Disorders
The third edition of the International Classification of Headache Disorders (ICHD-3) has now been published.1 This classification and the corresponding diagnostic criteria were initially released as a beta document in 2014; since then, they have been widely accepted and should now form the basis of all diagnosis and management of headache disorders in clinical practice as well as in research. The ICHD-3, like its predecessors, is hierarchical and allows diagnosis in different clinical settings, diagnosing at the first or second level in general practice and at the third, fourth, or fifth level in neurological practice or i...
Source: Lancet Neurology - March 14, 2018 Category: Neurology Authors: Jes Olesen Tags: Correspondence Source Type: research
[Articles] Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. (Source: Lancet Neurology)
Source: Lancet Neurology - March 12, 2018 Category: Neurology Authors: Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Kubala Havrdov á, Douglas Jeffery, Aaron Miller, Finn Sellebjerg, Diego Cada Tags: Articles Source Type: research
[Comment] Natalizumab in secondary progressive multiple sclerosis
Although several disease-modifying treatments are available for relapsing types of multiple sclerosis, additional treatment options for progressive types of multiple sclerosis are needed, especially since the available treatments tend to focus on patients who are actively relapsing. In this context, the ASCEND trial by Raju Kapoor and colleagues1 was a two-part study that assessed whether natalizumab slows disease progression unrelated to relapse in patients with secondary progressive multiple sclerosis. (Source: Lancet Neurology)
Source: Lancet Neurology - March 12, 2018 Category: Neurology Authors: Gilles Edan Tags: Comment Source Type: research
[Articles] Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. (Source: Lancet Neurology)
Source: Lancet Neurology - March 12, 2018 Category: Neurology Authors: Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Kubala Havrdov á, Douglas Jeffery, Aaron Miller, Finn Sellebjerg, Diego Cada Tags: Articles Source Type: research
[Comment] Natalizumab in secondary progressive multiple sclerosis
Although several disease-modifying treatments are available for relapsing types of multiple sclerosis, additional treatment options for progressive types of multiple sclerosis are needed, especially since the available treatments tend to focus on patients who are actively relapsing. In this context, the ASCEND trial by Raju Kapoor and colleagues1 was a two-part study that assessed whether natalizumab slows disease progression unrelated to relapse in patients with secondary progressive multiple sclerosis. (Source: Lancet Neurology)
Source: Lancet Neurology - March 12, 2018 Category: Neurology Authors: Gilles Edan Tags: Comment Source Type: research
[Articles] Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
We showed that riluzole prolongs survival in the last clinical stage of ALS; this finding needs to be confirmed in a prospective study, and treatment effects at stage 1 still need to be analysed. The ALS stage at which benefit occurs is important for counselling of patients before starting treatment. Staging should be used in future ALS clinical trials to assess the stage at which survival benefit occurs, and a similar approach could be used for other neurodegenerative diseases. (Source: Lancet Neurology)
Source: Lancet Neurology - March 7, 2018 Category: Neurology Authors: Ton Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, Ashley Jones, P Nigel Leigh, Gilbert Bensimon, Ammar Al-Chalabi Tags: Articles Source Type: research
[Comment] Riluzole, disease stage and survival in ALS
Following pivotal clinical trials in amyotrophic lateral sclerosis (ALS), approval of riluzole by the US Food and Drug Administration in 1995 was met with optimism. Despite being associated with a short survival benefit of 2 –3 months equating to a 9% increase in 1-year survival,1,2 the subsequent adoption of riluzole as a treatment for ALS was perhaps reflective of a desperate need for therapeutic options in the face of this devastatingly progressive disease.3 More than two decades after riluzole was first approved f or ALS, a more efficacious treatment is yet to be discovered. (Source: Lancet Neurology)
Source: Lancet Neurology - March 7, 2018 Category: Neurology Authors: Thanuja Dharmadasa, Matthew C Kiernan Tags: Comment Source Type: research
[Articles] Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
We showed that riluzole prolongs survival in the last clinical stage of ALS; this finding needs to be confirmed in a prospective study, and treatment effects at stage 1 still need to be analysed. The ALS stage at which benefit occurs is important for counselling of patients before starting treatment. Staging should be used in future ALS clinical trials to assess the stage at which survival benefit occurs, and a similar approach could be used for other neurodegenerative diseases. (Source: Lancet Neurology)
Source: Lancet Neurology - March 7, 2018 Category: Neurology Authors: Ton Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, Ashley Jones, P Nigel Leigh, Gilbert Bensimon, Ammar Al-Chalabi Tags: Articles Source Type: research
[Comment] Riluzole, disease stage and survival in ALS
Following pivotal clinical trials in amyotrophic lateral sclerosis (ALS), approval of riluzole by the US Food and Drug Administration in 1995 was met with optimism. Despite being associated with a short survival benefit of 2 –3 months equating to a 9% increase in 1-year survival,1,2 the subsequent adoption of riluzole as a treatment for ALS was perhaps reflective of a desperate need for therapeutic options in the face of this devastatingly progressive disease.3 More than two decades after riluzole was first approved f or ALS, a more efficacious treatment is yet to be discovered. (Source: Lancet Neurology)
Source: Lancet Neurology - March 7, 2018 Category: Neurology Authors: Thanuja Dharmadasa, Matthew C Kiernan Tags: Comment Source Type: research
[Articles] Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study
Brain β-amyloidosis alone did not predict progression to prodromal Alzheimer's disease within 30 months. Longer follow-up is needed to establish whether this finding remains consistent. (Source: Lancet Neurology)
Source: Lancet Neurology - February 27, 2018 Category: Neurology Authors: Bruno Dubois, Stephane Epelbaum, Francis Nyasse, Hovagim Bakardjian, Geoffroy Gagliardi, Olga Uspenskaya, Marion Houot, Simone Lista, Federica Cacciamani, Marie-Claude Potier, Anne Bertrand, Foudil Lamari, Habib Benali, Jean-Fran çois Mangin, Olivier Col Tags: Articles Source Type: research
